-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
*Only for medical professionals to read for reference, 1 minute a day, to give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add it to the editor's WeChat yxj_oncology).
Key points: JTO: Tilelizumab combined with chemotherapy can be used as a first-line treatment option for locally advanced or metastatic non-squamous non-small cell lung cancer.
JNCI: Obesity and multiple Cancer is closely related.
Mendelian randomized research conducted "deciphering" generic drugs: the first imitation! "Axitinib Tablets" Approved for Marketing JNCI: Relationship between Medicaid Expansion of Newly Diagnosed Young Cancer Patients and Cancer Stages and Differences 01JTO: Tilelizumab combined with chemotherapy can be used as locally advanced or metastatic non-squamous non First-line treatment options for small cell lung cancer A few days ago, JTO published a study online that tislelizumab combined with chemotherapy can be used as a first-line treatment option for locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
Article release screenshots Tilelizumab is an anti-PD-1 antibody with a unique design that minimizes its binding to FcɣR macrophages, thereby eliminating antibody-dependent phagocytosis.
Compared with chemotherapy alone, tislelizumab combined with chemotherapy can improve the clinical outcome of patients with advanced nsq-NSCLC.
In this open phase III trial (RATIONALE 304; NCT03663205), patients with stage IIIB/IV nsq-NSCLC confirmed by histology were randomly (2:1) divided into group A: tislelizone every 3 weeks Anti-platinum (carboplatin or cisplatin) and pemetrexed or group B: At first induction therapy with platinum and pemetrexed every 3 weeks, followed by intravenous maintenance therapy with pemetrexed every 3 weeks.
The primary endpoint is progression-free survival (PFS); the secondary endpoints are clinical response and safety/tolerability.
A total of 332 patients [n = 222 (A); n = 110 (B)] received treatment.
The median follow-up period of the study was 9.
8 months.
The PFS of the tislelizumab + chemotherapy group was significantly longer than that of the chemotherapy group alone (median PFS: 9.
7 months vs 7.
6 months; HR=0.
645; 95%CI: 0.
462~0.
902 ; P = 0.
0044).
In addition, compared with chemotherapy alone, the response rate of combination therapy is higher and the response duration is longer.
Hematological adverse events (AEs) were common in both treatment groups; most AEs reported were grade 1-2 in severity.
The most common AEs of grade ≥3 are related to chemotherapy, including neutropenia [44.
6%(A); 35.
5%(B)] and leukopenia [21.
6%(A); 14.
5%(B)].
Compared with chemotherapy alone, the addition of tislelizumab to chemotherapy can significantly prolong PFS, increase the response rate, and extend the duration of response.
Regardless of the cancer stage, it provides a new potential option for the first-line treatment of advanced nsq-NSCLC.
02JNCI: Obesity is closely related to a variety of cancers.
Mendelian randomized study is "deciphering".
A few days ago, JNCI published a study online to further determine the relationship between adult obesity and esophageal adenocarcinoma, colorectal cancer, endometrial cancer, ovarian cancer, The causal relationship between kidney cancer and pancreatic cancer, and the negative correlation between early obesity and breast cancer.
A screenshot of the article’s release.
Some observational studies have determined that at least 11 cancers are associated with obesity.
In recent years, Mendelian Random (MR) technology has provided supplementary information for traditional research methods.
We summarized and evaluated the existing evidence of MR research compared with traditional observational research in order to gain insight into the complexity between obesity and various cancers.
relationship.
The MR study further confirmed the causal relationship between adult obesity and esophageal adenocarcinoma, colorectal cancer, endometrial cancer, ovarian cancer, kidney cancer, and pancreatic cancer, as well as the negative correlation between early obesity and breast cancer.
MR research may explain the reasons for lifelong obesity, and it also implies that some observational studies usually only focus on the correlation of a single measurement, thereby ignoring the degree of correlation.
The MR study found that obesity is beneficial to reduce the risk of lung cancer.
This also supports the evidence that underweight increases the risk of lung cancer and that smoking increases the risk of lung cancer observed in some traditional observational studies.
However, there is no strong evidence for the association of MR studies with gallbladder cancer, gastric cardia cancer, and multiple myeloma.
In addition, more MR studies are needed to explore the effect of obesity on postmenopausal breast cancer and aggressive prostate cancer at different time points.
03 first imitation! "Axitinib Tablets" Approved for Marketing Recently, the official website of the State Food and Drug Administration showed that axitinib tablets (axitinib) generic drugs have been approved for marketing by the National Medical Products Administration (NMPA), which is the first imitation of the product.
Screenshot of the NMPA official website.
Axitinib is a kinase inhibitor that can inhibit tyrosine kinases associated with pathological angiogenesis, tumor growth and cancer progression at therapeutic doses.
Vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3.
04JNCI: The relationship between Medicaid expansion of newly diagnosed young cancer patients and cancer staging and differences A few days ago, JNCI published a study online that for the first time confirmed that Medicaid expansion and young cancer patients’ early cancer metastasis, urban-rural and ethnic differences at the time of diagnosis Relevance.
Screenshot of the article release Compared with older people, younger patients (YAs) have a higher uninsured rate and a later stage of cancer when they are diagnosed with cancer.
We studied the correlation between the expansion of the Affordable Care Act Medicaid and the insurance coverage and cancer staging of newly diagnosed young cancer patients.
Through the National Cancer Database, we included 309,413 young cancer patients aged 18-39, all of whom were diagnosed with cancer for the first time in 2011-2016.
The results of the study included the proportion of young patients who had no medical insurance at the first diagnosis, stage I (early) diagnosis, and stage IV (late) diagnosis.
We conducted a difference (DD) analysis to examine the results of states before and after the implementation of Medicaid expansion and states that did not implement medical expansion.
All statistical tests are two-sided tests.
The proportion of young cancer patients who were not covered by Medicaid during the expansion period declined more than that in the non-expansion period.
Compared with the non-expansion period, the overall proportion of patients diagnosed as stage I in the expansion period increased.
The improvement of black Hispanic patients was greater than that of non-Hispanic white patients.
Although the overall change in the diagnosis of stage IV was not statistically significant, compared with the non-dilated stage, the proportion of patients diagnosed with melanoma in the dilated stage was smaller.
References: [1] Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J , Leaw SJ, Zhang J, Lin X, Liang L, Yang N.
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol.
2021 May 1;7(5):709-717.
doi: 10.
1001/jamaoncol.
2021.
0366.
[2] Fang Zhe,Song Mingyang,Lee Donghoon et al.
The Role of Mendelian Randomization Studies in Deciphering the Effect of Obesity on Cancer.
[J ] .
J Natl Cancer Inst, 2021, undefined: undefined.
[3] https://mp.
weixin.
qq.
com/s/OYe1rWPOY-4CBnddMjuG7A[4] Ji Xu,Castellino Sharon M,Mertens Ann C et al.
Association of Medicaid Expansion with Cancer Stage and Disparities in Newly Diagnosed Young Adults.
[J] .
J Natl Cancer Inst, 2021, undefined: undefined.
Key points: JTO: Tilelizumab combined with chemotherapy can be used as a first-line treatment option for locally advanced or metastatic non-squamous non-small cell lung cancer.
JNCI: Obesity and multiple Cancer is closely related.
Mendelian randomized research conducted "deciphering" generic drugs: the first imitation! "Axitinib Tablets" Approved for Marketing JNCI: Relationship between Medicaid Expansion of Newly Diagnosed Young Cancer Patients and Cancer Stages and Differences 01JTO: Tilelizumab combined with chemotherapy can be used as locally advanced or metastatic non-squamous non First-line treatment options for small cell lung cancer A few days ago, JTO published a study online that tislelizumab combined with chemotherapy can be used as a first-line treatment option for locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC).
Article release screenshots Tilelizumab is an anti-PD-1 antibody with a unique design that minimizes its binding to FcɣR macrophages, thereby eliminating antibody-dependent phagocytosis.
Compared with chemotherapy alone, tislelizumab combined with chemotherapy can improve the clinical outcome of patients with advanced nsq-NSCLC.
In this open phase III trial (RATIONALE 304; NCT03663205), patients with stage IIIB/IV nsq-NSCLC confirmed by histology were randomly (2:1) divided into group A: tislelizone every 3 weeks Anti-platinum (carboplatin or cisplatin) and pemetrexed or group B: At first induction therapy with platinum and pemetrexed every 3 weeks, followed by intravenous maintenance therapy with pemetrexed every 3 weeks.
The primary endpoint is progression-free survival (PFS); the secondary endpoints are clinical response and safety/tolerability.
A total of 332 patients [n = 222 (A); n = 110 (B)] received treatment.
The median follow-up period of the study was 9.
8 months.
The PFS of the tislelizumab + chemotherapy group was significantly longer than that of the chemotherapy group alone (median PFS: 9.
7 months vs 7.
6 months; HR=0.
645; 95%CI: 0.
462~0.
902 ; P = 0.
0044).
In addition, compared with chemotherapy alone, the response rate of combination therapy is higher and the response duration is longer.
Hematological adverse events (AEs) were common in both treatment groups; most AEs reported were grade 1-2 in severity.
The most common AEs of grade ≥3 are related to chemotherapy, including neutropenia [44.
6%(A); 35.
5%(B)] and leukopenia [21.
6%(A); 14.
5%(B)].
Compared with chemotherapy alone, the addition of tislelizumab to chemotherapy can significantly prolong PFS, increase the response rate, and extend the duration of response.
Regardless of the cancer stage, it provides a new potential option for the first-line treatment of advanced nsq-NSCLC.
02JNCI: Obesity is closely related to a variety of cancers.
Mendelian randomized study is "deciphering".
A few days ago, JNCI published a study online to further determine the relationship between adult obesity and esophageal adenocarcinoma, colorectal cancer, endometrial cancer, ovarian cancer, The causal relationship between kidney cancer and pancreatic cancer, and the negative correlation between early obesity and breast cancer.
A screenshot of the article’s release.
Some observational studies have determined that at least 11 cancers are associated with obesity.
In recent years, Mendelian Random (MR) technology has provided supplementary information for traditional research methods.
We summarized and evaluated the existing evidence of MR research compared with traditional observational research in order to gain insight into the complexity between obesity and various cancers.
relationship.
The MR study further confirmed the causal relationship between adult obesity and esophageal adenocarcinoma, colorectal cancer, endometrial cancer, ovarian cancer, kidney cancer, and pancreatic cancer, as well as the negative correlation between early obesity and breast cancer.
MR research may explain the reasons for lifelong obesity, and it also implies that some observational studies usually only focus on the correlation of a single measurement, thereby ignoring the degree of correlation.
The MR study found that obesity is beneficial to reduce the risk of lung cancer.
This also supports the evidence that underweight increases the risk of lung cancer and that smoking increases the risk of lung cancer observed in some traditional observational studies.
However, there is no strong evidence for the association of MR studies with gallbladder cancer, gastric cardia cancer, and multiple myeloma.
In addition, more MR studies are needed to explore the effect of obesity on postmenopausal breast cancer and aggressive prostate cancer at different time points.
03 first imitation! "Axitinib Tablets" Approved for Marketing Recently, the official website of the State Food and Drug Administration showed that axitinib tablets (axitinib) generic drugs have been approved for marketing by the National Medical Products Administration (NMPA), which is the first imitation of the product.
Screenshot of the NMPA official website.
Axitinib is a kinase inhibitor that can inhibit tyrosine kinases associated with pathological angiogenesis, tumor growth and cancer progression at therapeutic doses.
Vascular endothelial growth factor receptors VEGFR-1, VEGFR-2 and VEGFR-3.
04JNCI: The relationship between Medicaid expansion of newly diagnosed young cancer patients and cancer staging and differences A few days ago, JNCI published a study online that for the first time confirmed that Medicaid expansion and young cancer patients’ early cancer metastasis, urban-rural and ethnic differences at the time of diagnosis Relevance.
Screenshot of the article release Compared with older people, younger patients (YAs) have a higher uninsured rate and a later stage of cancer when they are diagnosed with cancer.
We studied the correlation between the expansion of the Affordable Care Act Medicaid and the insurance coverage and cancer staging of newly diagnosed young cancer patients.
Through the National Cancer Database, we included 309,413 young cancer patients aged 18-39, all of whom were diagnosed with cancer for the first time in 2011-2016.
The results of the study included the proportion of young patients who had no medical insurance at the first diagnosis, stage I (early) diagnosis, and stage IV (late) diagnosis.
We conducted a difference (DD) analysis to examine the results of states before and after the implementation of Medicaid expansion and states that did not implement medical expansion.
All statistical tests are two-sided tests.
The proportion of young cancer patients who were not covered by Medicaid during the expansion period declined more than that in the non-expansion period.
Compared with the non-expansion period, the overall proportion of patients diagnosed as stage I in the expansion period increased.
The improvement of black Hispanic patients was greater than that of non-Hispanic white patients.
Although the overall change in the diagnosis of stage IV was not statistically significant, compared with the non-dilated stage, the proportion of patients diagnosed with melanoma in the dilated stage was smaller.
References: [1] Wang J, Lu S, Yu X, Hu Y, Sun Y, Wang Z, Zhao J, Yu Y, Hu C, Yang K, Feng G, Ying K, Zhuang W, Zhou J, Wu J , Leaw SJ, Zhang J, Lin X, Liang L, Yang N.
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer: A Phase 3 Randomized Clinical Trial.
JAMA Oncol.
2021 May 1;7(5):709-717.
doi: 10.
1001/jamaoncol.
2021.
0366.
[2] Fang Zhe,Song Mingyang,Lee Donghoon et al.
The Role of Mendelian Randomization Studies in Deciphering the Effect of Obesity on Cancer.
[J ] .
J Natl Cancer Inst, 2021, undefined: undefined.
[3] https://mp.
weixin.
qq.
com/s/OYe1rWPOY-4CBnddMjuG7A[4] Ji Xu,Castellino Sharon M,Mertens Ann C et al.
Association of Medicaid Expansion with Cancer Stage and Disparities in Newly Diagnosed Young Adults.
[J] .
J Natl Cancer Inst, 2021, undefined: undefined.
